Durata Therapeutics Announces Preclinical Data Supporting Clinical Development of Dalbavancin for the Treatment of Pneumonia

In Vitro Results Presented at IDWeek 2012

SAN DIEGO--(BUSINESS WIRE)--Durata Therapeutics (NASDAQ: DRTX) today announced in vitro study data that could help support a clinical development program to investigate its lead product candidate, dalbavancin, for the treatment of pneumonia. In this study, lung surfactant did not have a significant impact on the in vitro susceptibility of Staphylococcus aureus and Streptococcus pneumoniae to dalbavancin.

“We wanted to understand if surfactant would affect the potency of dalbavancin against bacteria of most concern to clinicians treating pneumonia patients”

“We wanted to understand if surfactant would affect the potency of dalbavancin against bacteria of most concern to clinicians treating pneumonia patients,” said Durata Therapeutics Chief Medical Officer Michael Dunne, M.D. “These data validate our assumption that surfactant does not significantly impact the in vitro potency of dalbavancin.”

Dalbavancin is currently under investigation in two ongoing, global, Phase 3 clinical trials for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible gram-positive bacteria.

The data from the study [The effect of lung surfactant on the in vitro activity of dalbavancin against Staphylococcus aureus and Streptococcus pneumoniae (Dunne, et al). Poster Number 1622] are being presented at the Novel Antimicrobial Agents session of IDWeek in San Diego. IDWeek is the first-ever combined meeting of four prestigious societies: the Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), and the Pediatric Infectious Diseases Society (PIDS).

Durata will display data from this and another dalbavancin-related study (Poster Number 1624) in San Diego Convention Center Halls F-H from Thursday, October 18 at 9:30 a.m. until Saturday, October 20 at 6:00 p.m. Dr. Dunne and co-presenting author Laura Koeth will be at the poster for discussion on Saturday, October 20, 12:30 – 2:00 p.m. PT.

For more information on the two studies presented at IDWeek 2012, visit www.duratatherapeutics.com/media-center/publications.

About Dalbavancin

Dalbavancin is an intravenous antibiotic product candidate under investigation for once-weekly dosing, which we believe may facilitate the treatment of patients with ABSSSI in both the in-patient and out-patient settings, potentially reducing the length of a patient’s hospital stay or avoiding hospital admission altogether, with an impact on the overall cost of care for these patients.

About Durata Therapeutics

Durata Therapeutics is a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. Durata is currently enrolling and dosing patients in two global Phase 3 clinical trials with its lead product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections, or ABSSSI.

Forward-looking statements

Statements contained in this press release contain forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements about the potential of clinical development program to investigate dalbavancin for the treatment of pneumonia. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the “Risk Factors” section of our most recent quarterly report on Form 10-Q, which is on file with the SEC and is also available on our website. In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. While we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our views change. Therefore, you should not rely on these forward-looking statements as representing our views as of any date subsequent to today.